Jonathan M. Meyer, MD

Department of Psychiatry, University of California San Diego, San Diego, California

JCP
Clozapine Monitoring in the Post-REMS World: Some Guidance for Clinicians
ASCP Corner

May 5, 2025

While the abolition of REMS for clozapine expands access, the change could create confusion. Among the most relevant examples are mismatches between FDA recommendations for lifetime monitoring and the...
,
JCP
Non-Dopaminergic Mechanisms for Schizophrenia Symptom Management
Educational Activity

August 7, 2023

Next generation therapeutics that work well, are better tolerated, and lead to improved outcomes may offer a different treatment approach for patients with schizophrenia.
,
JCP
Educational Activity

July 15, 2014

JCP
Commentary

February 19, 2014

,
JCP
How to Interpret Findings Concerning Newly Approved Antipsychotic Agents: Clinical Implications of the Lurasidone PEARL 2 Study
InfoPack

August 15, 2012

, , , et al
JCP
Original Research

December 16, 2009

, , , et al
JCP
Educational Activity

September 30, 2008

JCP
Article

December 14, 2007

JCP
Article

January 15, 2007

JCP
Original Research

May 15, 2003

JCP
Original Research

May 12, 2002

JCP
Article

January 14, 2001

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe